Emergent BioSolutions (EBS) Long-Term Deferred Tax (2010 - 2020)

Emergent BioSolutions' Long-Term Deferred Tax history runs 11 years deep, the most recent figure standing at $17.6 million for Q1 2020.

• In Q1 2020, Long-Term Deferred Tax changed N/A year-over-year to $17.6 million; the TTM figure through Mar 2020 stood at $17.6 million (changed N/A YoY), while the FY2019 annual figure was $13.4 million, changed 0.0% from the prior year.
• Long-Term Deferred Tax was $17.6 million for Q1 2020 at Emergent BioSolutions, up from $13.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $18.2 million in Q2 2016 to a low of $2.8 million in Q4 2017.
• Historically, Long-Term Deferred Tax has averaged $10.5 million across 5 years, with a median of $12.0 million in 2016.
• The sharpest annual moves came in 2017 and 2018: Long-Term Deferred Tax slumped 72.39% in 2017, then surged 378.57% in 2018.
• A 5-year view of Long-Term Deferred Tax shows it stood at $6.1 million in 2016, then tumbled by 54.07% to $2.8 million in 2017, then soared by 378.57% to $13.4 million in 2018, then changed by 0.0% to $13.4 million in 2019, then soared by 31.34% to $17.6 million in 2020.
• The last three Long-Term Deferred Tax figures came in at $17.6 million (Q1 2020), $13.4 million (Q4 2019), and $13.4 million (Q4 2018), per Business Quant data.